FAM72A promotes UNG2 degradation and mutagenesis in human cancer cells

Y Yuqing Feng P Philip Barbulescu C Chetan K. Chana M Melika Shirdarreh H Hong Yang (The First Affiliated Hospital of Air Force Military Medical University Xi’an China) L Lizhen Wu S Sami Mamand M Mohammad Kashem A Amin Zia M Ming Han J Julissa Tsao T Trevor Pugh (Princess Margaret Cancer Centre) D David Cescon D David G. Schatz (Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.) F Frank Sicheri A Alberto Martin R Rossanna C. Pezo

Abstract

Abstract Genetic lesions drive cancer development and progression, and understanding their origins will reveal the mechanisms of carcinogenesis. We showed that murine FAM72A promotes mutagenic DNA repair during antibody maturation by acting as a substrate adaptor of the CTLHMKLN1 E3 ligase to induce the proteasome degradation of Uracil DNA glycosylase 2 (UNG2), a pivotal enzyme of the base excision repair. In humans, the FAM72 gene has expanded to include four paralogues named FAM72A-D. Bioinformatic studies suggested that the human FAM72 genes are overexpressed in a broad range of cancers. However, the functional roles of FAM72A-D in human biology and cancer are unknown. Here, we show that FAM72 family members are minimally expressed in most healthy tissues except for thymus, and that FAM72A, B and D are overexpressed in primary tumorigenic tissues. Human FAM72 expression inversely correlates with UNG2 protein level in human cell lines and primary tumorigenic tissues suggesting that human FAM72 promotes UNG2 degradation. However, only FAM72A is able to bind to and induce UNG2 degradation in human cells. Our results suggest that the ability of FAM72A to induce UNG2 degradation contributes to neoplasia in a variety of cancer types by promoting mutagenic repair of genomic dUs.

Article Details

Volume / Issue Vol. 15, Issue 1
Published July 02, 2025
ISSN 2045-2322
Publisher Nature Portfolio

Journal Info

Scientific Reports

Nature Portfolio

ISSN: 2045-2322 Open Access Life Sciences

Authors (17)

Y

Yuqing Feng

P

Philip Barbulescu

C

Chetan K. Chana

M

Melika Shirdarreh

H

Hong Yang

The First Affiliated Hospital of Air Force Military Medical University Xi’an China

L

Lizhen Wu

S

Sami Mamand

M

Mohammad Kashem

A

Amin Zia

M

Ming Han

J

Julissa Tsao

T

Trevor Pugh

Princess Margaret Cancer Centre

D

David Cescon

D

David G. Schatz

Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.

F

Frank Sicheri

A

Alberto Martin

R

Rossanna C. Pezo